10-Q: Aspira Women's Health Reports Q2 2024 Results, Focuses on Growth and Innovation
Sentiment:
Quarterly Report
Aspira Women's Health reported its second quarter 2024 results, highlighting a focus on commercial growth, product innovation, and operational efficiency.
Capital raiseThe company completed a registered direct offering in January 2024, raising gross proceeds of $5.6 million.The company also raised $1.9 million in a private placement and $2.1 million in a warrant inducement transaction in July 2024.The company has an at-the-market offering agreement with H.C. Wainwright to sell shares of its common stock, having an aggregate sales price of up to $4.45 million.The company expects to raise capital through sources that may include public or private equity offerings, debt financings, the exercise of common stock warrants, collaborations, licensing arrangements, grants and government funding and strategic alliances, as well as its existing at-the-market and equity line of credit facilities.
Worse than expectedThe company's net loss and negative cash flow from operations are worse than expected.The company's product revenue decreased slightly compared to the same periods in 2023.The company's disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.The company received a deficiency letter from Nasdaq due to its Market Value of Listed Securities falling below the minimum requirement.
Summary
- Aspira Women's Health reported a net loss of $3.53 million for the three months ended June 30, 2024, and a net loss of $8.16 million for the six months ended June 30, 2024.
- Product revenue was $2.42 million for the quarter and $4.58 million for the six-month period, a slight decrease compared to the same periods in 2023.
- The company's gross profit margin was 58.6% for the quarter and 57.6% for the six-month period.
- Operating expenses decreased by $57,000 for the quarter and $1.6 million for the six-month period compared to 2023.
- The company completed a registered direct offering in January 2024, raising gross proceeds of $5.6 million.
- Aspira also raised $1.9 million in a private placement and $2.1 million in a warrant inducement transaction in July 2024.
- The company's cash and cash equivalents were $962,000 as of June 30, 2024.
- The company has an accumulated deficit of approximately $526.46 million and a working capital deficit of approximately $2.2 million as of June 30, 2024.
- The company has substantial doubt about its ability to continue as a going concern within one year after the date these consolidated interim financial statements are filed.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While there are positive developments in product innovation and market access, the company's financial performance and going concern risk are significant concerns. The material weaknesses in internal control and Nasdaq deficiency letter further contribute to a negative sentiment.
Positives
- The company has successfully implemented a revised commercial strategy, leading to increased test volume and sales representative productivity.
- The expansion of OvaWatch for longitudinal monitoring significantly increases the potential market for the company's tests.
- The company is making progress in developing new diagnostic tests for endometriosis, addressing a large unmet need.
- The company is actively pursuing reimbursement contracts with payers, resulting in increased coverage and higher average unit prices.
- The company has identified a significant number of biobank samples that can be sold for non-dilutive cash.
Negatives
- The company has incurred significant net losses and negative cash flows from operations since inception.
- The company has a working capital deficit and substantial doubt about its ability to continue as a going concern.
- Product revenue decreased slightly compared to the same periods in 2023.
- The company's disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
- The company received a deficiency letter from Nasdaq due to its Market Value of Listed Securities falling below the minimum requirement.
Risks
- The company's ability to continue as a going concern is uncertain due to significant net losses and negative cash flows.
- The company's ability to comply with Nasdaq's continued listing requirements is at risk.
- The company's ability to increase product sales volume and secure reimbursement from third-party payers is uncertain.
- The company's ability to develop and commercialize new diagnostic products and achieve market acceptance is subject to risks.
- The company's ability to compete successfully in the market is uncertain.
- The company's ability to obtain regulatory approval for future diagnostic products is subject to risks.
- The company's ability to maintain sufficient supplies of immunoassay kits from suppliers is subject to risks.
- The company's ability to protect and safeguard against cybersecurity risks and breaches is subject to risks.
- The company is subject to potential changes to coverage of Ova1 through its Medicare Administrative Carrier.
- The company is subject to potential changes in FDA oversight of LDTs, which could lead to additional compliance costs and delays.
Future Outlook
The company expects test volume to continue to increase for the remainder of 2024 as a result of its investment in key sales and marketing personnel and the launch of OvaWatch longitudinal testing. The company also expects research and development expenses to increase modestly over the third quarter of 2024, as a result of its focus on the product pipeline. The company expects sales and marketing expenses to modestly increase over the third quarter of 2024 as it continues to focus on the commercialization of OvaWatch. The company expects general and administrative expenses to remain flat for the third quarter of 2024.
Management Comments
- We are dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer.
- We plan to broaden our focus to the differential diagnosis of other gynecologic diseases that typically cannot be assessed through traditional non-invasive clinical procedures.
- We expect to continue commercializing our existing and new technology and to distribute our tests through our decentralized technology transfer service platform, Aspira Synergy.
- We also intend to continue to raise public awareness regarding the diagnostic superiority of Ova1Plus as compared to cancer antigen 125 (CA-125) on its own for all women with adnexal masses, as well as the superior performance of our machine learning algorithms in detecting ovarian cancer in different racial and ethnic populations.
- We plan to continue to expand access to our tests among Medicaid patients as part of our corporate mission to make the best care available to all women, and we plan to advocate for legislation and the adoption of our technology in professional society guidelines to provide broad access to our products and services.
- We continue to focus on three key initiatives: growth, innovation, and operational excellence.
Industry Context
The company operates in the women's health diagnostics market, focusing on ovarian cancer and endometriosis. The company's focus on AI-powered assays and non-invasive testing aligns with broader trends in the diagnostics industry. The company's efforts to expand access to its tests through Medicaid and partnerships with healthcare networks are also consistent with industry trends towards value-based care and patient-centric solutions.
Comparison to Industry Standards
- Aspira's Ova1Plus test competes with traditional methods like CA-125 for assessing ovarian cancer risk, but aims to provide superior sensitivity and specificity.
- The company's OvaWatch test is unique in the market as a commercially available blood test for initial and ongoing assessment of ovarian cancer risk in women with indeterminate or benign adnexal masses.
- The company's development of EndoCheck and EndoMDx for endometriosis diagnosis addresses a significant unmet need in the market, as current diagnostic methods are often invasive and delayed.
- The company's decentralized testing platform, Aspira Synergy, is similar to other point-of-care testing solutions, but is specifically designed for biomarker testing.
- The company's financial performance is below industry benchmarks for profitability, but this is common for early-stage diagnostic companies focused on research and development.
- The company's reliance on equity financing is also typical for companies in this sector, but the company's going concern risk is a significant concern.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | NA | Nicole Sandford | 2024-09-01 | Amendment to employment agreement, base salary decreased from $500,000 to $400,000, eligible for a cash bonus of up to $375,000, and a restricted stock unit award with an grant date fair value of $25,000. |
| President | NA | Sandra Milligan | 2024-09-01 | Amendment to employment agreement, base salary decreased from $400,000 to $320,000, eligible for a cash bonus of up to $200,000, and a restricted stock unit award with an grant date fair value of $20,000. |
| Interim Chief Financial Officer | NA | John Kallassy | 2024-08-15 | Consulting agreement, monthly retainer of $12,500, eligible for a 50% cash bonus, and a stock option grant of 25,000 shares. |
Legal Proceedings
- The company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the company's financial position or results of operations.
Stakeholder Impact
- Shareholders may experience significant dilution due to the company's need to raise capital through equity offerings.
- Employees may be affected by potential reductions in executive bonuses or replacement of cash compensation with equity grants.
- Customers may benefit from the company's continued development of new diagnostic tests and expansion of access to its products.
- Suppliers may be affected by potential reductions in professional services and consulting fees.
- Creditors may be affected by the company's financial difficulties and potential inability to repay its debts.
Next Steps
- The company plans to continue to focus on growth through the improved profitability, efficiency, and effectiveness of the sales and marketing teams.
- The company plans to continue to focus on the product pipeline, including the development of OvaMDx and EndoMDx.
- The company plans to continue to pursue reimbursement contracts with payers.
- The company plans to complete a comprehensive analysis of national, regional, and Integrated Delivery Network (IDN) payers to secure coverage for OvaWatch.
- The company plans to continue to identify opportunities for non-dilutive cash through sample dispositions.
- The company has until December 30, 2024, to regain compliance with Nasdaq's MVLS requirement.
Key Dates
| Date | Description |
|---|---|
| 2016-03-22 | Date of original DECD loan agreement. |
| 2020-12-03 | Date of second disbursement under the DECD loan agreement. |
| 2022-08-08 | Date of sponsored research agreement with Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Medical University of Lodz. |
| 2023-03-20 | Date of licensing agreement with Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Medical University of Lodz. |
| 2023-03-28 | Date of purchase agreement with Lincoln Park Capital Fund, LLC. |
| 2023-06-26 | Date the company was notified by the DECD that it satisfied all job creation and retention requirements under the loan agreement to receive forgiveness of $1,000,000. |
| 2023-07-20 | Date of securities purchase agreement for a registered direct offering. |
| 2024-01-24 | Date of securities purchase agreement for a registered direct offering. |
| 2024-01-26 | Date of closing of the 2024 registered direct offering. |
| 2024-02-06 | Date all pre-funded warrants were exercised. |
| 2024-05-06 | FDA published a final rule amending the definition of an IVD device to include IVDs manufactured by a clinical laboratory. |
| 2024-05-09 | Date of stockholder approval of an increase of 333,333 shares to the number of shares available for issuance under the 2019 Plan. |
| 2024-05-13 | Date of stockholder approval of an increase of 1,000,000 shares in the number of shares available for issuance under the 2019 Plan. |
| 2024-06-30 | End of the reporting period for the quarterly report. |
| 2024-07-01 | Date of securities purchase agreement for a private placement. |
| 2024-07-01 | Date the company received a deficiency letter from Nasdaq. |
| 2024-07-31 | Date of warrant inducement agreement. |
| 2024-08-02 | Date of agreement with H.C. Wainwright for an At the Market offering. |
| 2024-08-12 | Date of second amendment to employment agreement with Nicole Sandford. |
| 2024-08-12 | Date of amendment to employment agreement with Sandra Milligan. |
| 2024-08-12 | Date of appointment of John Kallassy as Interim Chief Financial Officer. |
| 2024-08-15 | Effective date of consulting agreement with John Kallassy. |
| 2024-09-01 | Effective date of the second amendment to employment agreement with Nicole Sandford. |
| 2024-09-01 | Effective date of the amendment to employment agreement with Sandra Milligan. |
| 2024-12-30 | Deadline for Aspira to regain compliance with Nasdaq's MVLS requirement. |
Keywords
Ovarian Cancer, Endometriosis, Diagnostic Tests, Biomarkers, Ova1, Overa, OvaWatch, EndoCheck, Aspira Synergy, CLIA Laboratory, Molecular Diagnostics, AI-Powered Assays, Reimbursement, Medicaid, Warrants, Equity Financing, Going Concern
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.